What is Tesamorelin?

A lab-made analog of the body's full 44-amino-acid growth-hormone-releasing factor (GHRF/GHRH), with a hexenoyl group added at one end, prepared as an acetate salt.

At a glance

What it is
A lab-made analog of the body's full 44-amino-acid growth-hormone-releasing factor (GHRF/GHRH), with a hexenoyl group added at one end, prepared as an acetate salt.
Also called
tesamorelin acetate · TH9507
US status
Approved drug exists, compounded ≠ itAn FDA-approved drug contains it. A compounded version is not that drug, and it is not FDA-approved.
Evidence
B: At least one decent human RCTFor the approved use, two multicenter, randomized, double-blind, placebo-controlled phase 3 trials (816 people randomized), each with a 26-week extension; for the uses programs sell (people without HIV, belly fat, muscle, "anti-aging"), one 12-month randomized trial of 60 people with abdominal obesity and low growth hormone, plus small trials in other groups, and no trial of a compounded product.
Safety signal
Well characterizedEGRIFTA SV/WR at the labeled use (label warnings: tumors, raised IGF-1, fluid retention, glucose intolerance, hypersensitivity)No data (unknown ≠ safe)Compounded or RUO tesamorelin, blends with ipamorelin, nasal or oral forms

Status checked Nov 16, 2026

What the human evidence looks like

What the human evidence looks like
Kind of studyPeopleWhat was looked at
Randomized controlled trials412Measured: visceral fat by CT scan, weight, waist, IGF-1, trunk fat and lean body mass in 412 adults aged 18 to 65 with HIV, lipodystrophy and excess belly fat (86% men), randomized 2 to 1 to EGRIFTA (273) or placebo (137) for 26 weeks, then an extension to week 52 in which some were re-randomized to placebo, in a multicenter, double-blind phase 3 trial (Study 1, NCT00123253, matched to Falutz 2007 by size and design).120
Randomized controlled trials404Measured: visceral fat by CT scan, weight, waist, IGF-1, trunk fat and lean body mass in 404 adults aged 18 to 65 with HIV, lipodystrophy and excess belly fat (84% men), randomized 2 to 1 to EGRIFTA (270) or placebo (126) for 26 weeks, then an extension to week 52 in which some were re-randomized to placebo, in a multicenter, double-blind phase 3 trial (Study 2, NCT00435136, matched to Falutz 2010 by size and design).121
Randomized controlled trials60Measured: visceral fat, belly fat under the skin and glucose measures in 60 adults without HIV who had abdominal obesity and reduced growth hormone, over 12 months, in a randomized trial (Makimura 2012).22
Randomized controlled trials152Measured: cognitive function in 152 adults aged 55 to 87, over 20 weeks, in a randomized trial (Baker 2012).24
Controlled studies61Measured: liver fat fraction in 61 people with HIV and fatty liver, over 12 months (Stanley 2019).23

What programs claim, and what has been studied

What programs claim, and what has been studied
What programs claimWhat has been studiedGrade
Reduces belly (visceral) fatTwo phase 3 randomized trials of EGRIFTA in adults with HIV and lipodystrophy, and one randomized trial of 60 people with obesity, measured belly (visceral) fat.122B
Weight lossThe label calls it weight neutral and says it is "not indicated for weight loss".1Contradicted
Builds muscleLean mass was a secondary measure in the trials in people with HIV.1C
Cognitive / anti-agingOne randomized trial of 152 people measured cognition.24C

What programs claim, and what has been studied
What programs claimWhat has been studiedGrade
Sleep, energy, skin, recoveryWe found no trial.26F
Compounded or "10 mg" vials equal EGRIFTAWe found no study, and the FDA's guidance gives no compounding pathway for biological products such as tesamorelin.9Contradicted
"FDA-approved peptide" for a compounded productA compounded product is not FDA-approved: only EGRIFTA SV and EGRIFTA WR are.3Contradicted

Safety facts

On the FDA label

  • The EGRIFTA SV and WR labels say not to use it with a disrupted hypothalamic-pituitary axis (after pituitary surgery or a pituitary tumor, head radiation or head injury), with active cancer, with allergy to tesamorelin or its inactive ingredients, or in pregnancy.12
  • The labels warn of a higher risk of tumors (neoplasms), because it releases growth hormone, "a known growth factor". They say any earlier cancer must be inactive and treated first, and to stop if cancer comes back.1
  • The labels say "The effects of prolonged elevations in IGF-1 levels are unknown." At 26 weeks, 47% of patients had IGF-1 above 2 standard deviation scores (SDS) and 36% above 3 SDS, and the labels say to monitor IGF-1.1
  • The labels warn of fluid retention: swelling (edema), joint pain and carpal tunnel syndrome, which pass or resolve after stopping.1
  • The labels report an HbA1c of 6.5% or more in 5% of patients versus 1% on placebo (hazard ratio 3.3). They say to check glucose before and during treatment, and to watch for eye damage (retinopathy) in people with diabetes.1
  • The labels report allergic reactions in 4% of patients (itching, redness, flushing, hives, rash) and injection-site reactions in 25% versus 14% on placebo. They say to consider stopping in acute critical illness.1
  • In the labels' 26-week table (543 people on EGRIFTA, 263 on placebo), the reactions were: injection-site reaction 17% vs 6%, joint pain 13% vs 11%, pain in a limb 6% vs 5%, muscle pain 6% vs 2%, swelling of the limbs (peripheral edema) 6% vs 2%, tingling 5% vs 2%, numbness 4% vs 2% and rash 4% vs 2%. In all, 740 people were treated in trials.1
  • The labels report "no clinically significant changes" in TSH, LH, ACTH or prolactin in trials.1
  • The labels report hydrocephaly in the offspring of rats given about 2 to 4 times the amount used in patients, and advise against breastfeeding (HIV transmission and unknown effects). They say it is not indicated for children and may speed their growth, and have "no information" on people over 65.1

Reports to the FDA

  • The FDA's adverse event database (FAERS, data to October 28, 2026) holds 3,625 reports naming tesamorelin or EGRIFTA, 840 marked serious; the most frequent terms are "product dose omission" (311), joint pain (286), injection-site pain (274), "drug ineffective" (193), weight increased (191), "incorrect dose" (178), injection-site bruising (163) and pain in a limb (163). Only 13 reports name "tesamorelin" as the product and nearly all name EGRIFTA, so FAERS says almost nothing about compounded tesamorelin; the reports are not checked, and they do not show cause.27

No data

  • We found no data on people who use compounded or "research use only" tesamorelin, people without HIV who use it long term, blends, women (84% to 86% of trial participants were men) or people over 65.126

Product quality

  • The FDA calls "research use only" tesamorelin an unapproved new drug. We found no published potency or contamination tests of compounded tesamorelin.151617181926

Compounded tesamorelin is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.

You can report a side effect to the FDA through MedWatch.

What a trustworthy program shows

  • Requires a prescription, after an evaluation by a prescriber licensed in your stateLegal
  • Says which product you get, EGRIFTA SV or WR (approved) or a compounded product, and for a compounded product names the pharmacy and the basis it compounds under789LegalGood practice
  • Does not call a compounded product "FDA-approved", and says EGRIFTA's approval covers HIV lipodystrophy only and is "not indicated for weight loss"1Legal
  • Does not sell it as "research use only"1516171819Legal
  • Screens for what the label rules out: active cancer, pregnancy, pituitary disease1Good practice
  • Orders lab tests before and during treatment: IGF-1 and glucose or HbA1c1Good practice
  • Sells a single ingredient, or names every active ingredient in a blend15Good practice
  • Lists the side effects: fluid retention, joint pain, glucose changes, injection-site reactions, allergy1Good practice
  • Warns athletes that WADA prohibits tesamorelin28Good practice
  • Shows the price, auto-renewal, cancellation and refund terms before checkoutLegalGood practice
  • Tells patients how to report a side effect to the FDA (MedWatch)1Good practice
  • Makes no "guaranteed results" claim and shows no before-and-after photosGood practice

  1. 1.
  2. 2.
    EGRIFTA WR (tesamorelin) prescribing information, set id 839334d3 (effective 2026-07-29)Tier 1: regulator or registerdailymed.nlm.nih.govread Nov 16, 2026↩
  3. 3.
    Drugs@FDA: BLA 022505 (EGRIFTA)Tier 1: regulator or registeraccessdata.fda.govread Nov 16, 2026↩
  4. 4.
    Approval letter, BLA 022505/S-020: EGRIFTA WR (Mar 25, 2025)Tier 1: regulator or registeraccessdata.fda.govread Nov 16, 2026↩
  5. 5.
    EGRIFTA 2 mg/vial label (S-010, revised Nov 2018)Tier 1: regulator or registeraccessdata.fda.govread Nov 16, 2026↩
  6. 6.
    openFDA drugsfda record for tesamorelin (BLA022505, ORIG-1 2010-11-10, Type 1)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
    FDA warning letter, NuScience Peptides LLC (Aug 24, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  16. 16.
    FDA warning letter, Royal Peptides LLC (Aug 24, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  17. 17.
    FDA warning letter, TXP Innovations LLC dba Tex Peptides (Aug 24, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  18. 18.
    FDA warning letter, Peak Performance Peptides (Aug 24, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  19. 19.
    FDA warning letter, Peptide Partners LLC (Aug 24, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.
  25. 25.
    ClinicalTrials.gov API v2, intervention "tesamorelin" (24 studies)Tier 1: regulator or registerclinicaltrials.govread Nov 16, 2026
  26. 26.
  27. 27.
    openFDA FAERS, reports naming tesamorelin or EGRIFTA (data to 2026-10-28)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
  28. 28.
    WADA Prohibited List 2026, S2.2 (GHRH and its analogues)Tier 1: regulator or registerwada-ama.orgread Nov 16, 2026↩
  29. 29.
    DEA controlled substances, alphabetical order (Nov 2026)Tier 1: regulator or registerdeadiversion.usdoj.govread Nov 16, 2026↩
  30. 30.
    GENOTROPIN (somatropin) prescribing informationTier 1: regulator or registerdailymed.nlm.nih.govread Nov 16, 2026
  31. 31.
  32. 32.
  33. 33.

We review programs, not peptides. This page reports what has been studied and what US regulators have said, with the source of each fact.

It is not medical advice: a decision about a medication is one to make with a licensed clinician.